FDA Affirms Regulatory Review Period for RECUVYRA Patent Extension

Summary

The US Food and Drug Administration (FDA) has confirmed the regulatory review period for the patent extension of RECUVYRA, a treatment for acute ischemic stroke, allowing the manufacturer to maintain its patent protection for a longer period.